ERIC SIEVERS, MD
FOUNDING BOARD MEMBER
Eric Louis Sievers is a pediatric oncologist serving more than 25 years in biotechnology and academia. He is an accomplished educator, speaker, inventor, and strategist, with a deep understanding of clinical trial design, regulatory strategy, and both early and late stages of clinical development. His clinical expertise spans across multiple cancer indications including leukemia, lymphoma, myelodysplastic syndromes, melanoma, and other solid tumors.
Dr. Sievers has authored/co-authored over 60 professional publications including manuscripts appearing in The New England Journal of Medicine, Nature Biotechnology, and The Journal of Clinical Oncology among others. He most recently served as Chief Medical Officer at Trillium Therapeutics in Toronto where he led the clinical development of a novel cancer treatment blocking the CD47 “do not eat” marker that is overexpressed by malignant cells. Earlier, he served as Senior Vice President of Clinical Development at Seattle Genetics, where he played a key leadership role developing and obtaining global approval of the antibody-drug conjugate ADCETRIS® indicated for patients with lymphoma. At the beginning of his career, Dr. Sievers cared for cancer patients for over a decade at the Fred Hutchinson Cancer Research Center and the University of Washington. During this time, he served as the lead investigator of phase 1 and pivotal trials that resulted in the approval of an antibody-drug conjugate MYLOTARG® indicated for patients with acute myeloid leukemia. He received his Medical and Bachelor of Arts degrees from Brown University. His personal interests include music, dance, travel, writing, and creative problem solving. He and his wife, Nicole, live with their five sons in Seattle.